Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities

Nephrology Dialysis Transplantation

Volumn 19, Issue 2, 2004, Pages 444-450

  Higgins, Robert ^a   Ramaiyan, Karam ^a   Dasgupta, Tanaji ^a   Kanji, Hemali ^a   Fletcher, Simon ^a   Lam, For ^a   Kashi, Habib ^a  

^a WALSGRAVE HOSPITAL   (United Kingdom)

Author keywords

Cyclosporin; Hyperkalaemia; Hyponatraemia; Kidney transplantation; Nephrotoxicity; Tacrolimus

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; BICARBONATE; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; FLUDROCORTISONE; FUROSEMIDE; LOOP DIURETIC AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYSTYRENESULFONATE CALCIUM; POTASSIUM; PREDNISOLONE; SODIUM; STEROID; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; DEHYDRATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; EXPERIENCE; FEMALE; FREQUENCY ANALYSIS; HUMAN; HYPERKALEMIA; HYPERURICEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTHESIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; POSTOPERATIVE PERIOD; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RECIPIENT; RETROSPECTIVE STUDY; SODIUM BLOOD LEVEL;

ADULT; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; HYPERKALEMIA; HYPONATREMIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PREVALENCE; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 1042292026     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg515     Document Type: Article

References (20)

1. Holt S, Moore K. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73: 673-674
2. Margreiter R, European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741-746
3. Ligtenberg G, Hene RJ, Blackestijin PHJ, Koomas MA. Cardiovascular risk factors in renal transplant patients: cylcosporin versus tacrolimus. J Am Soc Nephrol 2001; 12: 368
4. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-782
5. Higgins RM, Hart P, Lam FT, Kashi H. Conversion from tacrolimus to cyclosporin in stable renal transplant patients: safety, metabolic changes and pharmacokinetic comparison. Transplantation 2000; 69: 1736-1739
6. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423-428
7. Trompeter R, Filler G, Webb NJ et al. Randomised trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002; 17: 141-149
8. Pilmore HL, Faire B, Dittmer I. Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. Transplantation 2001; 72: 1703-1705
9. Sakamoto K, Yamada K, Arita S, Hamaguchi K, Kashiwabara H, Yokoyama T. Sodium-losing nephropathy and distal tubular damage of transplant kidneys with FK506 administration. Transplant Proc 1995; 27: 826-828
10. Rabb HA, Niles JL, Cosimi AB, Tolkoff-Rubin NE. Severe hyponatremia associated with combined pancreatic and renal transplantation. Transplantation 1989; 48: 157-159
11. Zaltzman JS. Post-renal transplantation hyponatraemia. Am J Kidney Dis 1996; 27: 599-602
12. Katari SR, Magnone M, Shapiro R et al. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. Clin Transplant 1997; 11: 237-242
13. Kramer HJ, Goldman R, Gonick HC. Salt-losing syndromes following renal transplantation. Am J Med 1972; 53: 368-376
14. Rokaw MD, West ME, Palevsky PM, Johnson JP. FK-506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells. Am J Physiol 1996; 271: C194-C202
15. Deppe CE, Heering PJ, Viengchareun S, Grabensee B, Farman N, Lombes M. Cyclosporine and FK506 inhibit transcriptional activity of the human mineralocorticoid receptor: a cell based model to investigate partial aldosterone resistance in kidney transplantation. Endocrinology 2002; 143: 1932-1941
16. Heering P, Ivens K, Aker S, Grabensee B. Distal tubular acidosis induced by FK506. Clin Transplant 1998; 12: 465-471
17. Woo M, Przepiorka D, Ippoliti C et al. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. Bone Marrow Transplant 1997; 20: 1095-1098
18. Kalbfleisch JH, Hebert LA, Lemann Jr J, Piering WF, Beres JA. Habitual excessive dietary salt intake and blood pressure levels in renal transplantation. Am J Med 1982; 73: 205-210
19. Aker S, Heering P, Kinne-Saffran E, Deppe C, Grabensee B, Kinne RK. Different effects of cyclosporine and FK506 on potassium transport systems in MDCK cells. Exp Nephrol 2001; 9: 332-340
20. DuBell WH, Gaa ST, Lederer WJ, Rogers TB. Independent inhibition of calcineurin and K+ currents by the immunosuppressant FK-506 in rat ventricle. Am J Physiol 1998; 275: H2041-H2052